The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1673
ISSUE 1673
April 3, 2023
Issue 1673
- Pegcetacoplan (Syfovre) for Geographic Atrophy in Age-Related Macular Degeneration
- Three Drugs for Atopic Dermatitis (Adbry, Cibinqo, and Rinvoq)
- In Brief: Rezvoglar - Another Insulin Glargine Product Interchangeable with Lantus
- Atezolizumab (Tecentriq) for Alveolar Soft Part Sarcoma (online only)
- Olutasidenib (Rezlidhia) for Acute Myeloid Leukemia (online only)
- In Brief: Fam-trastuzumab deruxtecan (Enhertu) for Breast Cancer (online only)
- In Brief: A New Indication for Abemaciclib (Verzenio) (online only)
- Dostarlimab (Jemperli) for Endometrial Cancer (online only)
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Pegcetacoplan (Syfovre) for Geographic Atrophy in Age-Related Macular Degeneration
April 3, 2023 (Issue: 1673)
The FDA has approved the complement C3 inhibitor
pegcetacoplan (Syfovre – Apellis) for treatment of
geographic atrophy (GA) secondary to age-related
macular degeneration (AMD). Given as a series of
monthly or every-other-month (EOM)...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.